BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32339567)

  • 1. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
    Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
    J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
    Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
    Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
    Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
    Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ Na
    Alvarez-Collazo J; López-Requena A; Alvarez JL; Talavera K
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
    Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
    Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
    Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
    Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
    PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
    Kim HJ; Kim BG; Park JE; Ki CS; Huh J; Youm JB; Kang JS; Cho H
    Sci Rep; 2019 Sep; 9(1):12997. PubMed ID: 31506521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
    Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
    Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
    Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
    Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome.
    Beyder A; Mazzone A; Strege PR; Tester DJ; Saito YA; Bernard CE; Enders FT; Ek WE; Schmidt PT; Dlugosz A; Lindberg G; Karling P; Ohlsson B; Gazouli M; Nardone G; Cuomo R; Usai-Satta P; Galeazzi F; Neri M; Portincasa P; Bellini M; Barbara G; Camilleri M; Locke GR; Talley NJ; D'Amato M; Ackerman MJ; Farrugia G
    Gastroenterology; 2014 Jun; 146(7):1659-1668. PubMed ID: 24613995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.
    Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA
    Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine.
    Wang Y; Mi J; Lu K; Lu Y; Wang K
    PLoS One; 2015; 10(6):e0128653. PubMed ID: 26068619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine.
    Tan BH; Valdivia CR; Song C; Makielski JC
    Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1822-8. PubMed ID: 16632547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant voltage-gated Na
    Clatot J; Zheng Y; Girardeau A; Liu H; Laurita KR; Marionneau C; Deschênes I
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1250-H1257. PubMed ID: 30118344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential calcium sensitivity in Na
    Abdelsayed M; Baruteau AE; Gibbs K; Sanatani S; Krahn AD; Probst V; Ruben PC
    J Physiol; 2017 Sep; 595(18):6165-6186. PubMed ID: 28734073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel.
    Abriel H; Cabo C; Wehrens XH; Rivolta I; Motoike HK; Memmi M; Napolitano C; Priori SG; Kass RS
    Circ Res; 2001 Apr; 88(7):740-5. PubMed ID: 11304498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
    Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
    Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.